MannKind and Amylin Embrace the Future of Diabetes Treatment
July 07 2011 - 8:16AM
Marketwired
In the United States alone, more than 21 million people suffer from
diabetes, and the number is growing at a rate of 10 percent
annually. This rapid growth has provided significant opportunities
for pharmaceutical companies who are able to develop new therapies
to address type 1 and 2 diabetes. The Bedford Report examines the
outlook for companies in the Healthcare Sector and provides equity
research on MannKind Corporation (NASDAQ: MNKD) and Amylin
Pharmaceuticals, Inc. (NASDAQ: AMLN). Access to the full company
reports can be found at:
www.bedfordreport.com/MNKD
www.bedfordreport.com/AMLN
According to Frost & Sullivan research titled "US Diabetes
Drug Delivery -- Patient Perspective," the future of diabetes
treatments is in the convenient drug delivery methods. Type-1
diabetic patients are most likely to prefer a twice-a-day oral
dosing regimen, while type-2 diabetic patients are also expected to
prefer a twice-a-day oral dosing regimen or a twice-a-day
patch.
MannKind's leading drug candidate, AFREZZA®, is an ultra-rapid
acting inhalable insulin that (if approved) will allow diabetes
patients to inhale AFREZZA before a meal. MannKind is trying to
show the FDA that the drug does not cause dangerous side effects to
a patient's heart.
The Bedford Report releases investment research on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
Amylin Pharmaceuticals is engaged in the discovery, development
and commercialization of drug candidates for the treatment of
diabetes, obesity and other diseases. Currently, Amylin produces
two drugs, Symlin and Byetta. Amylin says that Symlin "is the first
and only analogue of the human hormone amylin -- a partner to
insulin -- and a first-in-class diabetes therapy offering improved
glucose control with potential for weight loss."
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2024 to Jun 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2023 to Jun 2024